Zeitschrift für Blut und Lymphe

A System Biology Perspective to Overcoming the Challenges of JAK Inhibition Mon Therapy for Myeloproliferative Neoplasms: An Overview

Abstract

Alphonsus Ogbonna Ogbuabor1*, Peter Uwadiegwu Achukwu2, Silas Anayo Ufelle1,2, and Daniel Chukwuemeka Ogbuabor1,3

The JAK-STAT pathway mediates signals that are involved in hematopoiesis. Aberrant JAK-STAT signaling has been identified in myeloproliferative neoplasm making the pathway a novel therapeutic target for myeloproliferative neoplasms through the application of JAK inhibitors. A major limitation to therapy with the current JAK inhibitors is a lack of selectivity which results in toxicity to patients. It is thought that increasing the selectivity of inhibitors will reduce toxicity observed with JAK inhibition therapy. System biology is a novel technology that holds great potentials for increasing the selectivity of JAK inhibitors. Its Application to drug designing can broaden the spectrum as well as repurpose the available JAK inhibitors for improved clinical outcome and possible cure for myeloproliferative neoplasms. This review presents an overview on the role of system biology in JAK inhibition therapy for myeloproliferative neoplasms.